MARKET NEWS

Pneumagen Announces Positive Top Line Results From Phase 1 Study Evaluating a Product Designed for the Prevention & Treatment of Viral Respiratory Tract Infections
NGM Bio Announces Initiation of Phase 1/1b Clinical Study for the Treatment of Patients With Advanced Solid Tumors
Vallon Pharmaceuticals Reports Additional Pharmacokinetic & Pharmacodynamic Data From SEAL Study of ADAIR
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial
Qualigen Therapeutics’ Partner NanoSynex to Present Industry-Changing Technology at BioMed Israel

  FEATURED EDITORIAL

  COMPANY PROFILE

Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing of large and small molecules to pharmaceutical and biopharmaceutical customers. Curia’s 3,700 employees at 30 locations across the US, Europe, and Asia help its customers advance from curiosity to cure. Click here for more.

Video Spotlight: MilliporeSigma Formulation Development

  EXCLUSIVE ONLINE CONTENT

Aptar CSP Technologies’ Activ-Blister Solutions Now Available for Manufacturing in the EMEA Region

Aptar CSP Technologies’ Activ-Blister Solutions Now Available for Manufacturing in the EMEA Region

Aptar CSP Technologies recently announced a new manufacturing site able to produce its Activ-Blister™ Solutions for oral slide dose drugs in Europe. The move is part of….

Update on Positive Pre-Clinical Results From AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease

Update on Positive Pre-Clinical Results From AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease

Aeterna Zentaris Inc. recently provided an update on the positive results from pre-clinical studies of Aeterna’s Autoimmunity Modifying Biologicals (AIM Biologicals), for the potential treatment of Parkinson’s Disease (PD)…..

PCI Pharma Services Announces Major Manufacturing Expansion with 0-Million Investment 

PCI Pharma Services Announces Major Manufacturing Expansion with $100-Million Investment 

PCI Pharma Services recently announced a major expansion of capabilities and capacity in aseptic liquid fill-finish and sterile lyophilization technology with the investment of $100 million into the….

Artax Biopharma Closes Financing to Advance Clinical-Stage, First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Artax Biopharma Closes Financing to Advance Clinical-Stage, First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Artax Biopharma, Inc. recently announced the close of a $26-million financing round to develop AX-158, the company’s first oral small molecule immunomodulating agent…..

Hovione & JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

Hovione & JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

Hovione, the leader in spray drying and particle engineering, recently announced an exclusive license agreement for a preclinical ophthalmology program, JX08, with….

  WHITEPAPERS & WEBINARS

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..

  WHITEPAPERS & WEBINARS

WHITE PAPER: Controlled Synthesis of Lipid Nanoparticles Using the Automated Nanoparticle System

WHITE PAPER: Controlled Synthesis of Lipid Nanoparticles Using the Automated Nanoparticle System

ABSTRACT

Lipid nanoparticles (LNPs) are powerful carriers for the delivery of biotherapeutics and active pharmaceutical ingredients (APIs). They are attractive due to their size and biocompatibility, which are important factors when determining the efficacy of an encapsulated API. Particle Works’ …

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mecha­nisms of action continue to drive drug candidates’ phys­ical properties toward …

WHITE PAPER - Making Sub-Visible Particles Visible: Innovative Analytical Techniques for Detection & Identification

WHITE PAPER - Making Sub-Visible Particles Visible: Innovative Analytical Techniques for Detection & Identification

The demand for complex, often life-saving drug substances such as monoclonal antibodies, interferons, and peptides is on the rise, creating a greater need for innovative delivery mechanisms to administer these new therapeutics. For a variety of reasons, sub-visible particles can …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 25 – Lyophilization Manufacturing
June 1 – Capsules